An article on Herceptin in the Sept. 4, 1998, issue of BioWorld Today should have included, among other monoclonal antibodies, Gaithersburg, Md.-based MedImmune Inc.'s Synagis (palivizumab) to prevent respiratory syncitial virus infections in high-risk pediatric patients, and Mountain View, Calif.-based Protein Design Labs' Zenapax (daclizumab), to prevent acute kidney transplant rejection episodes.

No Comments